Manufacturing

Feliza Mirasol is the science editor for 

Articles

Lonza’s Joe Garrity and Jerry Jiang discuss the latest trends and challenges in commercializing new CGTs. 

Trends and Obstacles in the CGT Field (BIO 2024)

CGT Catapult and CATTI aim to standardize advanced therapy manufacturing with new aligned training standards.

CGT Catapult and CATTI Establish Shared Training Standards for Advanced Therapies

CGT Catapult will implement Cellular Origins' robotic platform in its Stevenage, UK, site to establish automated CGT manufacturing.

CGT Catapult and Cellular Origins Team Up to Develop Automated CGT Manufacturing

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.

Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio

Videos

Phillip Gregory, PhD, senior vice-president and head of Regeneron Cell Medicines, Regeneron, discussed how engineering receptor architecture can be a tool to improve CAR-T cell sensitivity to tumor antigens.

Using Receptor Architecture to Improve CAR-T Cell Sensitivity in Oncology (ASGCT 2024)

Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.

The Role of Bispecific Antibodies in Redirecting AAV Vectors (ASGCT 2024)

Experiments conducted by the downstream technology team at Spark Therapeutics involving metal ion-containing additives showed improved capsid clearance in AAV production.

ASGCT 2024: Additives Play a Role in Removal of Empty and Partial AAV Capsids

ProPharm and PBL have introduced a fully automated, enclosed cell factory manufacturing device.

New Cell Factory Box Launched by ProPharma and PBL for Automated CGT Manufacturing 

A new draft guidance issued by FDA covers human- and animal-derived materials used in the manufacture of advanced therapy medicinal products.



New FDA Draft Guidance Made Available for Materials Used in Manufacturing CGTs and Tissue-Engineered Therapeutics

In the new draft guidance, FDA provides recommendations on cell safety testing of human-sourced allogeneic cells for sponsor companies.

Manufacturing, Cell Therapies